Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001676170-26-000009
Filing Date
2026-06-03
Accepted
2026-06-03 17:04:16
Documents
1
Period of Report
2026-06-01

Document Format Files

Seq Description Document Type Size
1 form4-06032026_090612.html 4  
1 form4-06032026_090612.xml 4 6402
  Complete submission text file 0001676170-26-000009.txt   7902
Mailing Address C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300 SAN FRANCISCO CA 94010
Business Address
Coloma Jason V (Reporting) CIK: 0001676170 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-42490 | Film No.: 261061858

Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Issuer) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)